key: cord-0694344-x1413amb
authors: Devaraj, Sridevi; Poventud-Fuentes, Izmarie; Girotto, Matthew; Monroe, Jermaine; Boom, Julie; Delclos, George; Versalovic, James
title: SARS CoV-2 Serostatus amongst vaccinated employees at a pediatric hospital system
date: 2021-12-26
journal: Pract Lab Med
DOI: 10.1016/j.plabm.2021.e00261
sha: 132341b73bfdc10d626a636638a9d9babd28733d
doc_id: 694344
cord_uid: x1413amb

To gain insights on the heterogeneity of immune responses to vaccination against SARS-CoV-2 and to identify factors that could make individuals vulnerable to infection due to lack of response to vaccination, our hospital started offering free voluntary post-antibody testing against the spike protein IgG for all fully vaccinated employees. Post-vaccination response against SARS-CoV-2 was assessed using the FDA-EUA approved VITROS anti-SARS-CoV-2 IgG immunometric assay specific to the spike protein. Out of a total of 3266 antibody tests performed in fully vaccinated Texas Children's, 99.4% had a positive antibody response to the spike protein. From the 21 employees (0.6%) that had a negative response, 66.7% reported taking immunosuppressive drugs and/or biologics. Our data shows that most of the employees tested at our institution mounted an immune response to the immunogen in the vaccine. Post-vaccination antibody testing against SARS-CoV-2 can provide useful information to guide decisions about future vaccine doses.

As part of the efforts to combat the SARS-CoV-2 pandemic, the United States Food and Drug Administration (FDA) has given emergency use authorization (EUA) to three vaccines against SARS-CoV-2: Pfizer/BioNTech (now with full approval), Moderna NIAID, and Johnson & Johnson/Janssen (J&J).Texas Children's Hospital initiated its employee vaccination campaign against SARS-CoV-2 on December 15, 2020, after the EUA for Pfizer/BioNTech on December 11, 2020. As of September 5 th 2021], greater than 85% of the almost 15,000 workforce have been vaccinated (including medical staff and faculty). Beginning on February 21, 2021, the hospital also started offering free voluntary postvaccination antibody testing against spike protein IgG for all fully vaccinated employees, at least 2 weeks post second dose. The main goals of post-vaccination antibody testing were to gain insights on the heterogeneity of immune responses to vaccination and to identify factors that could make individuals more vulnerable to infection with SARS-CoV-2 due to lack of response to vaccination. In addition, we wished to provide additional knowledge to frontline employees who were seeking assurance that their vaccination was effective. Notable, in September 2021, the hospital also made the vaccine mandatory for its employees.

The study was approved by the Baylor College of Medicine Institutional Review Board. Using VITROS anti-SARS-CoV-2 IgG immunometric FDA-EUA approved test specific to the spike protein, postvaccination response against SARS-CoV-2 was assessed.

Results: Table 1 The 21 employees with negative antibody responses were subsequently interviewed to obtain more information on previous medical history and medications. Five out of these 21 employees (23.8%) who did not develop antibodies had been vaccinated with J&J vaccine, and the rest with Pfizer/BioNTech vaccine. Autoimmune diseases were reported by 10/21 (47.6%), including 2 rheumatoid arthritis, 2 psoriatic arthritis, 1 ankylosing spondylitis, 1 Crohn's disease and 4 non-specified ( Table 2) . Two of the non-responders were on immunosuppressive and biologic drugs, for organ transplantation and chronic lymphocytic leukemia, respectively. A total of 14/21 (66.7%) reported taking immunosuppressive drugs and/or biologics, including 4 (19%) of those with autoimmune disease. Lastly, two subjects did not have With further large scale studies, due to the heterogeneity in response, the need and timing of an additional dose can also be monitored by antibody testing, providing a personalized vaccination approach. Nevertheless, there are challenges that cannot be overlooked in the use of antibody testing after vaccination, including test harmonization, selection of protein moieties to detect, reliable diagnostic performance, and cost (6) .

Most of the employees that were tested at our institution generated antibodies against SARS-CoV-2 after being vaccinated (99.4%). These results provide reassurance that the vast majority of individuals successfully mounted an immune response to the immunogen in the vaccine (SARS-CoV-2 spike protein), likely resulting in protection against severe disease and hospitalization due to SARS-CoV- J o u r n a l P r e -p r o o f

Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. medRxiv

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals

Testing Is Not Currently Recommended to Assess Immunity After COVID-19 Vaccination: FDA Safety Communication

Interim Guidelines for COVID-19 Antibody Testing

Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How? Diagnostics (Basel)